Ablative radiotherapy for metastatic cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This international multicentre trial evaluates the effectiveness of stereotactic ablative radiotherapy (SABR) compared to standard care in patients with polymetastatic cancer. Participants will be randomly assigned to receive either SABR or standard treatment, with the aim of assessing overall survival, progression-free survival, quality of life, and treatment toxicity. The trial begins as a phase II study, with the potential to transition to a phase III trial based on initial findings. The study focuses on patients with multiple metastases who can safely receive targeted radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 or older
* willing and able to provide informed consent
* ECOG performance status 0-2
* Life expectancy \> or equal to 6 months
* Histologically confirmed malignancy with evidence of metastatic disease on imaging
* All sites of disease can be safely treated on a preliminary radiation plan
* \> or equal to 11 metastases (the primary tumor does not have to be controlled and can be included as a target if it can feasibly and safely be treated with SABR. If the primary tumor is treated, a minimum of 12 targets are required0 at least 11 metastases are required in addition to the primary tumor.)
* Investigations required within 12 weeks of enrollment:
* Brain: MRI is required for all patients with known untreated or previously treated brain metastases. MRI is strongly recommended for all tumor sites with a propensity to develop brian metastases.
* Body: 18-FDG PET/CT imaging is recommended, except for tumors where FDG uptake is not expected (e.g. prostate, renal cell carcinoma). PSMA-PET or choline-PET is recommended for prostate cancer. In situations where a PET scan is unavailable, or for tumors that do not take up radiotracer, a CT neck/chest/abdomen/pelvis and bone scan are required.
* Liver: For patients with liver metastases, a diagnostic or simulation MRI is required to confirm the total number of metastases.
* No plans for systemic therapy (i.e. chemotherapy, targeted agent, immunotherapy) for 3 months from the time of enrolment. Reasons may include: a break from systemic therapy is desired by the patient and medical oncologist, the patient declines next line of systemic therapy, or no further systemic therapy options are available. Exceptions include hormone therapy for breast cancer or prostate cancer, which may be continued.
* SABR or palliative radiotherapy should commence no later than 2 weeks after randomization.
* For patients with brain metastases that are going to be treated regardless of the study arm, there must be additional extracranial disease present that will be treated with SABR on Arm 2 and not treated with SABR on Arm 1.

Exclusion Criteria:

* Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Chrohn's disease in patients where the GI tract will receive radiotherapy, ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.
* For patients with liver metastases, moderate/severe liver dysfunction (Child-Pugh B or C)
* Substantial overlap with a previously treated radiation volume. Prior radiotherapy is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biologically effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. All such cases must be discussed with the study PI.
* Inability to treat all sites of disease. Any brain metastasis \>3 cm in size or a total volume of brain metastases greater than 30 cc.
* Solitary or dominant brian metastasis requiring surgical decompression.
* Radiologic evidence of spinal cord compression.
* Disseminated disease, including leptomeningeal metastases, peritoneal metastases/carcinomatosis, malignant pleural effusion, and lymphangitis carcinomatosis.
* Pregnant or lactating women.

Where it's running

• London Health Sciences Centre- London Regional Cancer Program
  London, Ontario, Canada Recruiting
• Centre Hospitalier de L'Universite de Montreal (CHUM)
  Montreal, Quebec, Canada Recruiting
• University Hospital of Zurich
  Zurich, Switzerland Recruiting

Study contacts

• Study coordinator: Timothy Nguyen, M.D.
• Email: Timothy.Nguyen@lhsc.on.ca
• Phone: 519-685-8500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Support program for parents living with advanced cancer

  This study tests whether adding experiential sessions to a psycho-educational program helps parents with advanced cancer communicate better with their children aged 10–25.

  Recruiting Université Libre de Bruxelles · Anderlecht · NCT07341815

• POLARIS — Ablative radiotherapy with immunotherapy for people with multiple metastatic lesions

  This pilot tests whether giving focused high-dose radiation to up to 10 metastatic tumors while patients are on immunotherapy helps people with advanced solid tumors who have 3–10 metastases.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07269080

• Adding Y‑NM600 imaging and targeted Y‑90 radiation to anti‑PD‑1/PD‑L1 treatment for metastatic cancer

  This will test whether giving radioactive Y‑NM600 imaging and a targeted Y‑90 radiation dose to people with metastatic cancer who are on anti‑PD‑1 or anti‑PD‑L1 medicines is safe and can help those medicines work better.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT07197671

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.